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An observational study of the lung
clearance index throughout childhood
in cystic fibrosis: early years matter
To the Editor:
The London Cystic Fibrosis Collaboration (LCFC) has prospectively followed a clinically diagnosed cohort
of infants with cystic fibrosis (CF) born in South East England since 1999 [1–4]. Over the past 20 years,
the LCFC has obtained comprehensive measures of lung function and structure, including measures of
ventilation inhomogeneity (lung clearance index (LCI)) and high-resolution computed tomography
(HRCT) scans. By pre-school age, 73% of this cohort had LCI above the limits of normal, compared with
7% with abnormal forced expiratory volume in 0.5 seconds (FEV0.5) [1]. Children with elevated LCI
during pre-school years also had worse lung function at early school age [2]. The aim of this study was to
investigate how LCI changes across childhood to better understand to what extent LCI results at
pre-school age are an indicator of lung disease severity in adolescence.
Details of the LCFC cohort have been previously published [1, 4, 5]. Starting in 2013, adolescents with CF
and their contemporaneous controls, aged 12–17 years, were recruited for follow-up. Anthropometric
measurements, clinical examination and lung function testing were performed on a single day, along with
HRCT in adolescents with CF. Inclusion criteria included clinical stability at the time of test (no change in
respiratory symptoms or medication within the previous 2 weeks). Ethical approval was granted from the
NHS Health Research Authority National Research Ethics Service (reference 13/LO/0322) and written
informed consent obtained.
Multiple breath washout (MBW) was performed using a mass spectrometer with SF6 as the tracer gas [2, 3].
Apart from a face mask being used for pre-school and mouthpiece for older subjects, identical equipment
was used as for previous study visits. Quality control was undertaken to ensure the same settings and
algorithms were applied for all study visits. An elevated LCI was defined as ⩾1.96 z-scores using published
reference equations [6]. Spirometry was performed after MBW [7]. Forced expiratory volume in 1 s (FEV1)
was the primary outcome. Abnormal FEV1 was defined as ⩽−1.96 z-scores (lower limit of normal (LLN))
using the 2012 Global Lung Function Initiative (GLI) reference equations [8]. For longitudinal analysis of
FEV, z-scores for FEV at time ‘t’ in pre-school children were calculated from FEV0.75 if FEV1 was not
available (zFEVt). Anthropometric z-scores were calculated from the British 1990 growth charts [9].
Low-dose (100 kV) volumetric CT scans were acquired at total lung capacity, followed by three additional
expiratory scans, in non-contiguous fashion performed at pre-determined levels. CT scans were scored
using Brody-II [10], blinded to any previous results or current clinical condition, by the same radiologist
who had scored the school-age scans. The total Brody-II CF-CT score was used as the primary outcome,
with secondary outcomes being the sub-scores of bronchiectasis, peribronchial thickening and air trapping.
Mixed-effects linear regression with random intercepts and slopes was used to determine the rate of LCI
change through childhood using all available data from the LCFC. An exchangeable correlation structure
was used, and an interaction between age and group was used to determine whether the rate of change
differed between the healthy and CF groups. Linear regression was used to estimate the factors
(determined a priori) associated with FEV1 z-scores during adolescence. The same analysis was repeated
using LCI and CT at adolescence as outcomes. Statistical analysis was performed using STATA (Version
15.0).
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43 subjects with CF tested at pre-school were followed up to adolescence; four subjects had either died or
undergone lung transplantation. In those who died (one post-lung transplant, one following assessment
for urgent lung transplantation and one unknown), the reported LCI values at pre-school were 11.4, 8.0
and 7.3, with corresponding zFEVt: −3.5, 0.1 and −1.0. In the surviving lung transplant subject,
pre-school LCI was 11.92 and zFEV1 −1.1.
Anthropometrically, the CF group included in these analyses was similar to contemporaneous controls
during pre-school years, whereas by adolescence, the controls were significantly taller and heavier,
although there was no significant difference in zBMI. 37% (13/35, 8 unknown) CF subjects were positive
for Pseudomonas aeruginosa within 12 months prior to their pre-school test, and similarly, 41% at
adolescent follow-up (17/41, 2 unknown). Subjects with CF had significantly lower zFEV1 compared with
the healthy group at adolescent follow-up (mean difference −1.25 (95% CI −1.86; −0.65), but only 30%
had a zFEV1 value below the LLN. LCI was more than 3 units higher in the CF group compared with the
healthy adolescents (mean difference 3.22, 95% CI 2.29; 4.16). The median total Brody-II CF-CT score was
19 (interquartile range 10–46); range 0–102 (maximum possible score of 243).
LCI increased (deteriorated) with age in the CF group by 0.18 units per year (95% CI 0.14; 0.21; intra-class
correlation 0.67). While there was a small, statistically significant, increase in LCI in the control group with
age, this was significantly faster in CF (figure 1). The majority (88%) of the CF subjects had abnormal LCI
at adolescence; using published upper limits of normal [6], pre-school LCI had a sensitivity of 77% (95% CI
58.9; 90.4) and a specificity of 66% (95% CI 9.43; 99.2), positive predictive value 96% (95% CI 79.6; 99.9)
and negative predictive value 22.2% (95% CI 2.81; 60.0) (area under the curve 0.72 (95% CI 0.39; 1.0)) to
predict abnormal LCI at adolescence. FEVt at pre-school had a similar sensitivity (80% (95% CI 44.4; 97.5)
but a much lower specificity for abnormal LCI at adolescence (27%; 95% CI 11.6; 47.8).
There were no statistically significant associations between demographic characteristics (sex, genotype, age
at diagnosis, age at pre-school visit) and adolescent outcomes (zFEV1, LCI and CT score), nor was there a
statistically significant association with the acquisition of P. aeruginosa prior to their pre-school visit.
Pre-school LCI was positively associated with adolescent LCI (slope 0.97 (95% CI 0.50; 1.44), n=34) and
adolescent CT (6.22 (1.5; 10.9), n=33), but not adolescent zFEV1 (−0.27 (−0.54; 0.001), n=43). In
comparison, pre-school FEV1 was associated with adolescent zFEV1 (0.39 (0.02; 0.76), n=38) but not
adolescent LCI (−0.73 (−1.54; 0.08), n=35) or CT (−0.89 (−8.7; 6.9), n=34). Similar results were observed
for the association between pre-school LCI and adolescent bronchiectasis, bronchial wall thickness and air
trapping sub-scores of the Brody-II CF-CT.
Our findings confirm that LCI at pre-school age correlates with LCI at adolescence in clinically diagnosed
children with CF. Higher LCI values during pre-school are associated with worse lung function and
structure during adolescence. Together with the finding that LCI is more sensitive than spirometry during
pre-school years, these longitudinal data confirm that LCI is a useful tool to identify young children who
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FIGURE 1 Change in lung clearance index (LCI) with age in healthy subjects (HC) and those with cystic fibrosis (CF) throughout childhood. a) Rate
of change in LCI with age in health (slope 0.04 (95% CI 0.002; 0.08) and CF (slope 0.18 (95% CI 0.14; 0.21). The rate of change in CF was
significantly different from the healthy group (interaction coefficient −0.05 (95% CI −0.09; −0.002). Results represent mean LCI with 95%
confidence intervals for the CF group (dashed line, pale shaded area) and contemporaneous controls (solid line, darker shaded area),
respectively. b) Individual changes in LCI in health (solid line) and CF (dashed line).
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In this observational cohort, an elevated LCI during pre-school years was an indicator of worse lung
disease throughout childhood and adolescence. This is highly relevant to current populations of children
with CF, even though most will now have been diagnosed by newborn screening (NBS). Although more
recent, newborn screened, cohorts have milder phenotypes, there remain individuals with elevated LCI at
pre-school age [11], and our data suggest this is of prognostic significance. More recent pre-school studies
in NBS subjects have also identified this period as a critical window for monitoring early lung disease in
children with CF; the LCI can detect significant lung function deterioration, and was associated with acute
worsening during pulmonary exacerbations [12]. In addition, the SHIP (Saline Hypertonic in
Preschoolers) study suggests that LCI is responsive to treatment in this age group [13]. Thus, using LCI to
identify the deterioration of lung function in early childhood may lead to early intervention to alter the
course of lung disease, and long-term outcomes.
This is the first study to report that pre-school LCI is associated with chest CT structural abnormalities in
adolescence. This is consistent with a cross-sectional study which reported significant associations between
school-age (range 7–16 years; mean 9.8 years) LCI and extent of total disease, bronchiectasis and air
trapping on chest CT in an Australian NBS cohort [14].
A major strength of this study is the prospective follow-up when patients were clinically stable, with
measurements performed at a single centre, and the inclusion of a contemporaneous healthy control group
measured using the same equipment and protocol. Despite the small number of subjects overall, this is a
unique cohort with comprehensive physiology outcomes. In this study, the same radiologist used the Brody-II
CF-CT to score scans at school age and adolescence, to facilitate comparison of results. While newer CF scoring
systems are now available [15], we felt it inappropriate to change pre-specified analysis plans. The long interval
between study visits meant that only limited clinical data were captured at the study visits, with potential for
missing data. Furthermore, since clinicians were not blinded to lung function results, they may have changed
management. The unexpected rise in LCI in healthy adolescents could either indicate natural increases in LCI
in health [16] or a potential bias which may have increased the number of adolescents identified with abnormal
LCI, but neither would have influenced conclusions regarding the relative changes in LCI over time.
LCI measured during the pre-school years correlates with LCI at adolescence and is associated with chest
CT abnormalities at adolescence. Elevated pre-school LCI is an ominous warning of impaired adolescent
lung function in clinically diagnosed children with CF, and further emphasises a window of opportunity to
intervene at an early age to improve outcomes.
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